400 related articles for article (PubMed ID: 33201837)
21. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma.
Mo R; Peng J; Xiao J; Ma J; Li W; Wang J; Ruan Y; Ma S; Hong Y; Wang C; Gao K; Fan J
Tumour Biol; 2016 Jul; 37(7):9797-806. PubMed ID: 26810069
[TBL] [Abstract][Full Text] [Related]
22. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
Rausch M; Rutz A; Allard PM; Delucinge-Vivier C; Docquier M; Dormond O; Wolfender JL; Nowak-Sliwinska P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208775
[TBL] [Abstract][Full Text] [Related]
23. Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
Wu Z; Peng Y; Xiong L; Wang J; Li Z; Ning K; Deng M; Wang N; Wei W; Li Z; Dong P; Yu C; Zhou F; Zhang Z
Cancer Med; 2022 Oct; 11(19):3674-3686. PubMed ID: 35476809
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
26. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
27. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
[TBL] [Abstract][Full Text] [Related]
28. Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma.
Dufies M; Verbiest A; Cooley LS; Ndiaye PD; He X; Nottet N; Souleyreau W; Hagege A; Torrino S; Parola J; Giuliano S; Borchiellini D; Schiappa R; Mograbi B; Zucman-Rossi J; Bensalah K; Ravaud A; Auberger P; Bikfalvi A; Chamorey E; Rioux-Leclercq N; Mazure NM; Beuselinck B; Cao Y; Bernhard JC; Ambrosetti D; Pagès G
Commun Biol; 2021 Feb; 4(1):166. PubMed ID: 33547392
[TBL] [Abstract][Full Text] [Related]
29. Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma.
Ruan H; Li X; Yang H; Song Z; Tong J; Cao Q; Wang K; Xiao W; Xiao H; Chen X; Xu G; Bao L; Xiong Z; Yuan C; Liu L; Qu Y; Hu W; Gao Y; Ru Z; Chen K; Zhang X
Exp Cell Res; 2017 Sep; 358(2):269-278. PubMed ID: 28684115
[TBL] [Abstract][Full Text] [Related]
30. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.
Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
[TBL] [Abstract][Full Text] [Related]
32. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
33. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
[TBL] [Abstract][Full Text] [Related]
34. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
35. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
37. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
Ambrosetti D; Coutts M; Paoli C; Durand M; Borchiellini D; Montemagno C; Rastoin O; Borderie A; Grepin R; Rioux-Leclercq N; Bernhard JC; Pagès G; Dufies M
BJU Int; 2022 Jan; 129(1):80-92. PubMed ID: 34107167
[TBL] [Abstract][Full Text] [Related]
38. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
39. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract][Full Text] [Related]
40. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
